CLINICAL GUIDELINES GENETIC TESTING

AIM General Clinical Guideline

OPEN THE GENERAL CLINICAL GUIDELINE

Access Archived Guidelines

OPEN ARCHIVED GENETIC TESTING GUIDELINES

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING

The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines. AIM Clinical Appropriateness Guidelines for Genetic Testing are developed through a rigorous process integrating evidence-based literature with expert review.

The Guidelines do not address coverage, benefit or other plan specific issues. Applicable federal and state coverage mandates take precedence over these clinical guidelines. If requested by a health plan, AIM will review requests based on health plan medical policy/guidelines in lieu of the AIM Guidelines.

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR HEREDITARY CARDIAC DISEASE

The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Hereditary Cardiac Disease includes testing for inherited arrhythmias and cardiomyopathies.

OPEN THE GUIDELINES

COMING SOON GENETIC TESTING FOR HEREDITARY CARDIAC DISEASE EFFECTIVE SEPTEMBER 4, 2022

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR HEREDITARY CANCER SUSCEPTIBILITY

The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Hereditary Cancer Susceptibility includes screening for hereditary cancer predisposition syndromes.

OPEN THE GUIDELINES

COMING SOON GENETIC TESTING FOR HEREDITARY CANCER SUSCEPTIBILITY EFFECTIVE SEPTEMBER 4, 2022

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR MOLECULAR TESTING OF SOLID AND HEMATOLOGIC TUMORS AND MALIGNANCIES

The testing addressed in the AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies includes genetic testing and gene expression profiling of solid and hematologic tumors for the purpose of diagnosis or for information related to treatment selection, prognosis, or recurrence risks.

OPEN THE GUIDELINES

COMING SOON GENETIC TESTING FOR MOLECULAR TESTING OF SOLID AND HEMATOLOGIC TUMORS AND MALIGNANCIES EFFECTIVE SEPTEMBER 4, 2022

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR PHARMACOGENOMIC TESTING

The testing addressed in the AIM Clinical Appropriateness Guidelines for Pharmacogenomic Testing includes genotyping to predict response to certain medications and testing for gene mutations associated with coagulation disorders.

OPEN THE GUIDELINES

COMING SOON GENETIC TESTING FOR PHARMACOGENOMIC TESTING EFFECTIVE SEPTEMBER 4, 2022

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR SINGLE-GENE AND MULTIFACTORIAL CONDITIONS

The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Single-Gene and Multifactorial Conditions includes single-gene testing, multigene diagnostic panels, testing for variants associated with multifactorial conditions, chromosomal microarray analysis, and human leukocyte antigen (HLA) histocompatibility testing.

OPEN THE GUIDELINES

COMING SOON GENETIC TESTING FOR SINGLE-GENE AND MULTIFACTORIAL CONDITIONS EFFECTIVE SEPTEMBER 4, 2022

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR CHROMOSOMAL MICROASSAY ANALYSIS, WHOLE EXOME AND WHOLE GENOME SEQUENCING

The testing addressed in the AIM Clinical Appropriateness Guidelines for Chromosomal Microassay Analysis, Whole Exome and Whole Genome Sequencing includes the diagnostic use of whole exome and genome sequencing in the evaluation of rare disease.

OPEN THE GUIDELINES 

COMING SOON GENETIC TESTING CHROMOSOMAL MICROASSAY ANALYSIS, WHOLE EXOME AND WHOLE GENOME SEQUENCING EFFECTIVE SEPTEMBER 4, 2022

AIM CLINICAL APPROPRIATENESS GUIDELINES FOR GENETIC TESTING FOR REPRODUCTIVE CARRIER SCREENING AND PRENATAL DIAGNOSIS

The testing addressed in the AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis includes carrier testing for familial mutations and common and ethnic genetic diseases; preimplantation screening and diagnosis; prenatal screening and diagnosis; and testing for recurrent pregnancy loss and infertility.

OPEN THE GUIDELINES

COMING SOON GENETIC TESTING FOR REPRODUCTIVE CARRIER SCREENING AND PRENATAL DIAGNOSIS EFFECTIVE SEPTEMBER 4, 2022

Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. (dba InformedDNA®). © 2020 Informed Medical Decisions, Inc. All rights reserved.

SUBMIT COMMENTS